Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHAMSC-101 is an autologous adipose-derived mesenchymal stem cell therapy being developed by CHA for reproductive medicine indications including premature ovarian insufficiency, endometrial disorders, and improvement of genetic stability of IVF oocytes. The product uses a patient's own adipose tissue-derived MSCs as the active therapeutic component and is intended to promote tissue repair and modulate local inflammation through paracrine regenerative effects rather than a single defined molecular target. Based on the provided company pipeline information, CHAMSC-101 is positioned as an early-stage cell therapy program under the Korean regenerative medicine framework, corresponding to Phase 1 level clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CHAMSC-101.